All topics
lifeevergreen
Research-ready episode

The Proven Program That Saves Money and Nobody Pays For

一个被证明能省钱的预防项目，为什么没人买单

What this research must answer

A constellation film about the economics of prevention. One proven program saves money and almost nobody joins it; a payment system pays for billable disease events; public systems drift toward hospitals even when they promise prevention; the wellness industry sells the promise of health while treatment industries profit from its failure; the first mass prevention product is a drug that collides with the same budget wall; and random biological risk means hospitals will never be empty. The frontier — longevity medicine and the healthspan economy — is the market's attempt to make health purchasable, and the same incentive logic decides who gets paid.

这是一部关于'预防经济学'的星座式纪录片。一个被证明能省钱的预防项目几乎没人参加；按项目付费的医疗系统只为'可计费的疾病事件'付钱；连公开承诺预防的英国 NHS 都把医院份额从47%推高到58%；保健产业卖'健康的承诺'，治疗产业则从承诺的失败中赚钱；第一个规模化'预防产品'是药物，却撞上同一堵预算墙；而随机生物风险意味着医院永远不会空。前沿——长寿医学与健康跨度经济——是市场把'健康'变成商品的尝试，而同样的激励逻辑将决定谁最终拿到这笔钱。

Opening tension

A prediabetic employee qualifies for a free, twice-weekly lifestyle program with two decades of trial evidence behind it. The program saves the payer more than $4,500 per participant in two years. Medicare added it as a covered benefit in 2018. Six years later, 9,015 people had enrolled — less than 1% of eligible beneficiaries. Cut to an HR director: 'Before we knew it, we spent half a million dollars [on GLP-1 drugs] and were projected to go up to $1.2 million the following year.' Same condition, same budget, opposite funding.

Opening variants
  1. ·

    The empty waiting list

    A free, proven program. A $4,500 per-person saving. Fewer than 1% of eligible seniors enrolled six years after Medicare began paying for it.

    The cost-saving paradox as opening pressure; the mystery is why the cheap fix goes unfunded.

  2. ·

    The HR call

    'We spent half a million dollars and were projected to go up to $1.2 million.' An HR director reads the GLP-1 line item; we cut to the program that would have cost a fraction of that.

    A real decision owner and a real dollar figure; opens on the moment prevention and treatment collide on one budget.

  3. ·

    The right drift

    A minister promises to move care out of hospitals. Fifteen years later, the hospital share of the NHS budget has risen from 47% to 58%. Why can't a system that promises prevention actually drift left?

    Institutional puzzle opening; reframes the question from individual habits to system wiring.

How the episode moves
  1. 01

    If a proven prevention program saves $4,552 per participant in two years, why does almost nobody join it?

    Medicare began paying for the Diabetes Prevention Program in 2018; six years later 9,015 people had enrolled — under 1% of eligible beneficiaries. Meanwhile chronic disease drives 90% of the $4.5 trillion US health spend, and half of chronic conditions are preventable.

    MedPage Today 2025; ASPPH 2025

    Why would a system that spends $4.5 trillion on disease refuse to scale the intervention that saves money?

  2. 02

    What is the payment system actually rewarding?

    Fee-for-service pays for billable events: diagnoses, procedures, drugs. Prevention is a non-event — nothing to bill, so no revenue. The National Academy of Medicine says prevailing payment structures reward volume and intensity over prevention; STATnews notes hospitals, insurers, pharmaceutical companies, and manufacturers all benefit from a system organized around diagnosis and treatment.

    NAM 2026; STATnews 2026

    If the money is wired to treatment, can a public system that promises prevention resist the pull?

  3. 03

    Can a publicly funded system resist that pull?

    The UK's Darzi review found the NHS promised a 'left shift' to prevention while the share of the NHS budget spent on hospitals rose from 47% to 58% between 2006 and 2022 — 'no left shift, just a right drift.' Community prevention programs that demonstrably reduce demand stay 'nice-to-have' next to hospital targets.

    Guardian/Darzi 2024; STATnews 2026

    If even a public monopoly drifts toward hospitals, what is the deeper economics of prevention that makes it uncommercial?

  4. 04

    What is the deeper economics of prevention that makes it uncommercial?

    Geoffrey Rose's prevention paradox: a population strategy helps millions of people a little, and each individual almost not at all — so no individual experiences a benefit worth paying for. Meanwhile the wellness economy — 6.8 trillion dollars in 2024 — monetizes the promise of health outside the medical system, selling products and programs that sit between the food industry and the hospital.

    Rose 1985; Cambridge CPH; GWI 2025

    If prevention doesn't pay individuals, does the wellness industry's flagship product actually work?

  5. 05

    Does workplace wellness — the largest corporate prevention purchase — actually save money?

    The landmark Song & Baicker randomized trial (JAMA 2019) found no significant difference in clinical measures, healthcare spending, or employment outcomes after 18 months. RAND's 2013 study of large employers found roughly $157 saved per employee per year against roughly $150 in program cost — cost neutral at best. The prevention market sells hope; the treatment market sells certainty.

    JAMA 2019; RAND 2013

    If lifestyle programs don't reliably pay, why do chronic diseases keep rising while the food environment stays unchanged?

  6. 06

    Who built the food environment feeding the chronic disease pipeline?

    The CDC finds Americans get 55% of their calories from ultra-processed food. The formulation industry monetizes the cause; the medical system monetizes the consequence. Food-as-medicine estimates: national medically tailored meals could avert 1.6 million hospitalizations and save $13.6 billion in year one; produce prescriptions for diabetic, food-insecure patients could avert 292,000 cardiovascular events — yet these programs remain marginal pilots.

    CDC NCHS 2025; Tufts True Cost of Food 2023

    Is there any prevention product big enough to break the system's incentive wall?

  7. 07

    What happens when prevention finally becomes a product — a drug?

    GLP-1 agonists: 34% of non-elderly employer-insured adults qualify; coverage among firms with 5,000+ workers jumped from 28% to 43% in a year; employers report drug spend tripling and premiums projected to rise 5-14%; many now gate coverage behind lifestyle programs (10% to 34%) or drop weight-loss coverage entirely. The first mass prevention market collides with the same budget wall that starved the cheap program.

    Peterson-KFF 2025; Korn Ferry 2026

    If even the most profitable prevention product hits the wall, what's left of the claim that healthy living empties hospitals?

  8. 08

    Can everyone who eats well, moves well, and uses healthy products really make hospitals obsolete?

    No. Two-thirds of cancer mutations arise from random stem-cell replication errors, not lifestyle (Tomasetti & Vogelstein). Trauma, infection, genetics, and aging guarantee acute demand. Prevention shifts the demand curve; it does not eliminate the hospital. The healthspan movement — Medicine 3.0, Outlive — is not wrong that risk compounds; it is selling measurement and early action inside a system that still pays for disease.

    Science 2017; Hopkins Medicine 2024; RACGP 2026

    So what actually changes when the market finally prices 'health' as a product?

  9. 09

    What does the future of 'health as a product' actually look like?

    The longevity economy — GLP-1s, longevity clinics, wearables, 'escape velocity' claims — is the market's attempt to make health purchasable. But the same incentive logic returns: whoever can bill for the outcome captures the value. The opening question flips: it was never that hospitals would have nothing to do. It is that health only gets built when someone can charge for it — and today the people who can charge are selling treatment, formulation, or supplements, not community health.

    TechCrunch 2025; GWI 2025

    Payoff: a cost-saving program with an empty waiting list is not a failure of science. It is a failure of who gets paid.

Story bank
  1. opening-pressure

    The MDPP waiting list

    9,015 enrollees in six years against a pool of eligible beneficiaries; the most proven prevention program in US medicine with an empty waiting list.

  2. historical-turn

    Darzi's right drift

    The NHS promised 'left shift'; hospital budget share rose 47% to 58% between 2006 and 2022; 'no left shift, just a right drift.'

  3. mechanism

    Fee-for-service

    Payment attaches to billable events; prevention produces no event, no revenue, no capacity.

  4. conceptual-reversal

    Rose's prevention paradox

    A population strategy helps many people a little and each individual almost not at all, so no individual experiences a benefit worth paying for.

  5. conceptual-reversal

    The wellness null

    Song & Baicker's workplace wellness RCT: no significant effect on clinical measures or spending after 18 months; RAND: roughly cost neutral.

  6. institution

    The food environment

    55% of US calories from ultra-processed food; formulation monetizes cause, medicine monetizes consequence; food-as-medicine pilots estimate 1.6M hospitalizations averted and $13.6B net savings.

  7. application

    GLP-1 as the first mass prevention product

    34% of employer-insured adults qualify; coverage at largest firms jumped 28% to 43% in a year; spending tripled for some employers; premiums projected +5-14%.

  8. countercase

    The patient who did everything right

    Two-thirds of cancer mutations arise from random stem-cell replication errors; trauma, infection, and aging guarantee acute demand; prevention shifts the curve but cannot empty the hospital.

  9. frontier

    The longevity economy

    $6.8 trillion wellness economy and the healthspan movement selling measurement and early action inside a system that still pays for disease.

How the system works
Input
A patient's risk of chronic disease and a provider's time, with no billable event attached to keeping the patient well.
Transformation
Fee-for-service payment converts clinical encounters into revenue per service; prevention produces no service event, so it produces no revenue and no provider capacity.
Output
A system that reliably funds late-stage treatment and only sporadically funds early intervention, regardless of cost-effectiveness.
Limit
This explains underfunding, not biology: even perfectly funded prevention cannot remove random mutation, trauma, or aging.
Mechanism cards

  1. Fee-for-service reimbursement

    Input
    A clinical encounter; the patient's condition and the provider's time.
    Transformation
    Each service is converted into a billable claim; revenue grows with volume of procedures, tests, and drugs.
    Output
    Provider income and system capacity aligned to treatment events; prevention produces no claim.
    Limit
    Explains underfunding of prevention but not its biology; some preventive services (immunizations) do bill and do scale.
    Evidence
    NAM 2026; STATnews 2026

  2. Rose's prevention paradox

    Input
    A small risk reduction applied across an entire population.
    Transformation
    Population-wide strategies shift the incidence curve; each individual's benefit is small and mostly invisible.
    Output
    Large population-level gains in disease avoided.
    Limit
    No individual experiences a benefit worth paying for, so commercial and political demand stays low.
    Evidence
    Rose 1985; Cambridge CPH

  3. Ultra-processed food environment

    Input
    Engineered formulations optimized for palatability and shelf life.
    Transformation
    Marketing and formulation drive consumption; 55% of US calories now come from ultra-processed food.
    Output
    A population-level metabolic burden that later becomes billable chronic disease.
    Limit
    Individual 'responsibility' framing ignores the structural exposure the industry engineered.
    Evidence
    CDC NCHS 2025

  4. GLP-1 as the first mass prevention product

    Input
    Obesity and metabolic risk; a continuous prescription.
    Transformation
    The drug alters appetite and satiety signals, producing weight loss without behavior change.
    Output
    Risk reduction as a billable, scalable product — the first prevention the payment system pays for at scale.
    Limit
    Cost, discontinuation, and payer churn; the same budget wall that starved lifestyle prevention now gates the drug.
    Evidence
    Peterson-KFF 2025

  5. Stochastic cancer risk

    Input
    Stem cell divisions over a lifetime.
    Transformation
    Random replication errors accumulate; about two-thirds of cancer mutations are not attributable to inherited or environmental factors.
    Output
    A baseline cancer risk that lifestyle cannot eliminate.
    Limit
    Prevention can reduce incidence, but cannot remove the random component; hospitals keep a guaranteed role.
    Evidence
    Tomasetti et al., Science 2017

  6. Wellness commercialization

    Input
    The consumer's desire to stay healthy, in a system that doesn't pay for it.
    Transformation
    The wellness economy ($6.8T) packages hope as products and programs outside the medical system.
    Output
    A parallel market selling health as a purchase, with weak outcome guarantees.
    Limit
    Its flagship RCT (workplace wellness) was a null result; the promise is monetized before the outcome is proven.
    Evidence
    GWI 2025; Song & Baicker, JAMA 2019
Where this changes a real decision

SignalProven, cost-saving prevention exists (NDPP: $4,552 average two-year direct-medical-cost reduction per enrollee).

Decision ownerCMS and employer benefit managers, the payers who would capture the savings.

ThresholdA payer must decide whether to fund a non-billable lifestyle intervention against immediate drug and premium pressure.

ActionMedicare covered MDPP in 2018 but enrollment stayed under 1% of eligible; employers buying GLP-1 coverage hit 43% among the largest firms in one year.

ConsequenceThe payer's budget flows to the expensive, billable path; the cheap, proven path stays underused — while premium and drug costs grow.

Application chains

  1. Medicare pays for prevention, enrollment stays empty

    SignalNDPP saves $4,552 per enrollee over two years in direct medical costs.

    Decision ownerCMS and Medicare beneficiaries.

    ActionCover the program (2018); operate only 1.5 sites per 100,000 beneficiaries; enroll under 1% of eligible.

    ConsequenceThe savings stay on the table while chronic disease keeps driving 90% of spend.

  2. Employers buy the prevention drug, then hit the wall

    Signal34% of employer-insured adults qualify for GLP-1 therapy; coverage at 5,000+ worker firms rose 28% to 43% in a year.

    Decision ownerEmployer benefit managers.

    ActionCover the drug, then gate it behind lifestyle programs (10% to 34% of firms) or drop weight-loss coverage.

    ConsequencePharmacy spend tripled for some plans; premiums projected +5-14%; the first mass prevention market meets the same budget wall.

  3. Food as medicine stays a pilot

    SignalMedically tailored meals could avert 1.6M hospitalizations and save $13.6B in year one; produce prescriptions could avert 292,000 cardiovascular events.

    Decision ownerPayers and CMS innovation center.

    ActionRun pilots and a bundled-payment test; keep programs marginal relative to drug and procedure spend.

    ConsequenceProven, low-cost interventions remain underfunded while billable treatment scales.

The limit this episode must keep

Prevention is not automatically profitable or effective. Song & Baicker's workplace wellness RCT found no significant improvement in clinical measures or spending after 18 months, and RAND found wellness roughly cost-neutral. Two-thirds of cancer mutations are random replication errors, so perfect lifestyle cannot empty hospitals; trauma and aging guarantee acute demand. The honest conclusion is not 'prevention is a scam' but 'prevention only scales where someone can charge for the outcome'.

Key sources